n-oleoylethanolamine has been researched along with oleylamide* in 3 studies
3 other study(ies) available for n-oleoylethanolamine and oleylamide
Article | Year |
---|---|
Improved anti-obesity effect of herbal active and endogenous lipids co-loaded lipid nanocarriers: Preparation, in vitro and in vivo evaluation.
Topics: Animals; Anti-Obesity Agents; Antioxidants; Body Weight; Calorimetry, Differential Scanning; Capsaicin; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Liberation; Endocannabinoids; Feeding Behavior; Kinetics; Lipids; Mice; Nanostructures; Obesity; Oleic Acids; Particle Size; Static Electricity; Temperature | 2019 |
Evaluation of fatty acid amides in the carrageenan-induced paw edema model.
While it has long been recognized that Delta(9)-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis, and other cannabinoid receptor agonists possess anti-inflammatory properties, their well known CNS effects have dampened enthusiasm for therapeutic development. On the other hand, genetic deletion of fatty acid amide hydrolase (FAAH), the enzyme responsible for degradation of fatty acid amides, including endogenous cannabinoid N-arachidonoyl ethanolamine (anandamide; AEA), N-palmitoyl ethanolamine (PEA), N-oleoyl ethanolamine (OEA), and oleamide, also elicits anti-edema, but does not produce any apparent cannabinoid effects. The purpose of the present study was to investigate whether exogenous administration of FAAs would augment the anti-inflammatory phenotype of FAAH (-/-) mice in the carrageenan model. Thus, we evaluated the effects of the FAAs AEA, PEA, OEA, and oleamide in wild-type and FAAH (-/-) mice. For comparison, we evaluated the anti-edema effects of THC, dexamethasone (DEX), a synthetic glucocorticoid, diclofenac (DIC), a nonselective cyclooxygenase (COX) inhibitor, in both genotypes. A final study determined if tolerance to the anti-edema effects of PEA occurs after repeated dosing. PEA, THC, DEX, DIC elicited significant decreases in carrageenan-induced paw edema in wild-type mice. In contrast OEA produced a less reliable anti-edema effect than these other drugs, and AEA and oleamide failed to produce any significant decreases in paw edema. Moreover, none of the agents evaluated augmented the anti-edema phenotype of FAAH (-/-) mice, suggesting that maximal anti-edema effects had already been established. PEA was the most effective FAA in preventing paw edema and its effects did not undergo tolerance. While the present findings do not support a role for AEA in preventing carrageenan-induced edema, PEA administration and FAAH blockade elicited anti-edema effects of an equivalent magnitude as produced by THC, DEX, and DIC in this assay. Topics: Amidohydrolases; Analysis of Variance; Animals; Arachidonic Acids; Cannabinoids; Carrageenan; Dexamethasone; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Edema; Endocannabinoids; Ethanolamines; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oleic Acids; Polyunsaturated Alkamides | 2008 |
Design, synthesis and activity as acid ceramidase inhibitors of 2-oxooctanoyl and N-oleoylethanolamine analogues.
The synthesis of novel N-acylethanolamines and their use as inhibitors of the aCDase is reported here. The compounds are either 2-oxooctanamides or oleamides of sphingosine analogs featuring a 3-hydroxy-4,5-hexadecenyl tail replaced by ether or thioether moieties. It appears that, within the 2-oxooctanamide family, the C3-OH group of the sphingosine molecule is required for inhibition both in vitro and in cultured cells. Furthermore, although the (E)-4 double bond is not essential for inhibitory activity, the (E) configuration is required, since the analogue with a (Z)-4 unsaturation was not inhibitory. None of the oleamides inhibited the aCDase in vitro. Conversely, with the exception of N-oleoylethanolamine and its analogs with S-decyl and S-hexadecyl substituents, all the synthesized oleamides inhibited the aCDase in cultured cells, although with a relatively low potency. We conclude that novel aCDase inhibitors can evolve from N-acylation of sphingoid bases with electron deficient-acyl groups. In contrast, chemical modification of the N-oleoylsphingosine backbone does not seem to offer an appropriate strategy to obtain aCDase inhibitors. Topics: Animals; Cell Line, Transformed; Drug Design; Endocannabinoids; Enzyme Inhibitors; Ethanolamines; Galactosylgalactosylglucosylceramidase; Humans; Liver; Lysosomes; Mitochondria; Molecular Structure; Oleic Acids; Rats | 2006 |